Having trouble accessing articles? Reset your cache.

Management tracks: Browne out as Revance CEO; plus CytomX, Aligos, Angion, Savonix and Global Cancer Technology

Revance Therapeutics Inc. (NASDAQ:RVNC), which is developing neuromodulators for aesthetic and therapeutic indications, hired board member Mark Foley as president

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE